Remibrutinib Offers Sustained Relief for Chronic spontaneous Urticaria, Long-Term Data Show
A new oral treatment option, remibrutinib, is demonstrating lasting efficacy and a favorable safety profile for adults battling chronic spontaneous urticaria (CSU), according to data presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Meeting and recently approved by the FDA in September 2025.
A New Hope for Patients with Persistent Itch and Hives
For individuals with CSU who find little relief from standard antihistamine therapy, remibrutinib – a highly selective, reversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Novartis – represents a important advancement. The findings stem from a pooled analysis of the phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials, evaluating the drug’s performance over a 52-week period.
Rapid and Durable Symptom Reduction
The analysis focused on adults experiencing moderate-to-severe CSU despite ongoing antihistamine treatment. Researchers measured efficacy using the Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7). Results revealed that remibrutinib provided both rapid and sustained improvements across all key measures when compared to placebo.
A statistically significant and clinically meaningful reduction in hive severity and itch was observed as early as week 2. By week 52, patients treated with remibrutinib experienced a mean 74.8% reduction from baseline in UAS7, a 73.6% reduction in ISS7, and a 75.2% reduction in HSS7. These improvements were not only quick to materialize but also maintained throughout the entire 52-week treatment duration.
Positive Outcomes even After Switching from Placebo
Notably, patients who transitioned from placebo to remibrutinib at week 24 also saw substantial improvements in UAS7, ISS7, and HSS7 within just one week of starting the medication, with efficacy continuing through week 52.At week 25, percentage improvements were 66.8% for UAS7, 65.6% for ISS7, and 67.5% for HSS7.These gains further solidified with improvements of 75.5%, 74.2%, and 75.9% in UAS7, ISS7, and HSS7, respectively, by week 52.
“These outcomes indicate that remibrutinib provides fast and sustained symptom relief for patients with CSU who remained symptomatic despite treatment with second-generation H1 antihistamines,” the study authors concluded.
A Well-Tolerated safety Profile
The overall safety profile of remibrutinib was deemed favorable and generally well-tolerated over the 52-week observation period. the proportion of patients reporting adverse events (AEs) was similar between those receiving remibrutinib (64.9%) and those receiving placebo (64.7%). Importantly, no serious AEs were attributed to remibrutinib use.
Addressing an Unmet Need with an Oral Option
The availability of an oral treatment is especially encouraging, according to clinicians. “It’s very exciting to have an oral option for our patients that have failed high-dose oral antihistamines,” one allergy and immunology physician explained. “Currently, the only medications that were approved and indicated for CSU were injectable medications, so it’s very exciting to have an option for patients that is oral and not an injection, as a lot of patients are wary or afraid of getting an injection-especially an injection that would need to be repeated.”
Another study investigator noted the potential for improved adherence, stating, “Seeing patients already noticing symptom improvement within 3 days really leads to helping keep patients consistent on dosing.” The rapid onset of symptom relief coudl be a key factor in encouraging long-term treatment adherence.
Remibrutinib’s approval and promising long-term data offer a new and effective treatment pathway for individuals struggling with the debilitating symptoms of chronic spontaneous urticaria.
